The U.S. Food and Drug Administration approved Nereus (tradipitant) from Vanda Pharmaceuticals based on three pivotal studies, including two phase III real‑world trials with subjects on boats. The approval covers prevention of motion‑sickness vomiting and positions Nereus as the first new pharmacologic option for the indication in over 40 years. Vanda reported plans to launch the oral therapy early in 2026 and disclosed a sharp market reaction to the decision. Clinical dossiers cited by Vanda included real‑world challenge trials that measured vomiting prevention in maritime settings. The approval clears a near‑term commercial pathway for Vanda and may reshape travel‑medicine formularies; Nereus’s mechanism targets neurokinin‑1 pathways implicated in emetic signaling. Analysts will watch early launch uptake and prescribing patterns in emergency and travel clinics.